Last updated 5 days ago
A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)
454 patients around the world
Available in Puerto Rico, Argentina, United States
The primary objective of the study is to evaluate the efficacy of felzartamab compared to placebo on proteinuria in participants with Immunoglobulin A nephropathy (IgAN). The main secondary objective of the study is to evaluate the efficacy of felzartamab compared to placebo on kidney functions in participants with IgAN. The additional secondary objectives are to evaluate the efficacy of felzartamab compared to placebo on additional clinical endpoints and to assess the pharmacokinetics (PK) and immunogenicity of felzartamab.
Biogen
3Research sites
454Patients around the world
This study is for people with
Nephropathy
Iga nephropathy
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Biopsy-confirmed diagnosis of IgAN within the past 10 years prior to signature of the informed consent form (ICF).For participants with diabetes mellitus type 2, biopsy confirmation of IgAN diagnosis must be done within the past 24 months prior to signing the ICF.An eGFR ≥ 30 mL/min/1.73m² at Screening as calculated using the 2021 chronic kidney disease epidemiology (CKD-EPI) creatinine formula.An eGFR of ≥ 20 and < 30 mL/min/1.73m² is acceptable for the cohorts 3 and 4.Proteinuria of ≥ 1.0 gram per day (g/day) or UPCR ≥0.8 gram per gram (g/g) as assessed by an adequate 24-hour urine collection.Clinically stable on a maximally tolerated dose or maximally approved dose of angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) for at least 12 weeks prior to Screening.Participants who are intolerant of ACEI or ARB must discuss this with the Medical Monitor prior to randomization.Participants may also be using sodium-glucose cotransporter-2 inhibitors (SGLT2is), endothelin receptor antagonists (ERAs) approved for the treatment of IgAN, and/or mineralocorticoid receptor antagonists (MRAs) as long as the dose is stable for at least 12 weeks prior to Screening.Participants should remain on stable doses of these background medications for the duration of the study.Once the ICF is signed and thereafter, the doses cannot be changed during the study nor the drugs discontinued except if deemed related to an AE.Participants using sparsentan will not be permitted to use simultaneous ACEI or ARB medication.
- Secondary forms of IgAN, indicated by the presence of any other systemic disease potentially leading to IgA deposits as determined by the Investigator.History of rapidly progressive variant of IgAN, defined as eGFR loss by > 50% per 3 months and not explained by changes in renin-angiotensin system (RAS) blockade or other factors.Nephrotic syndrome presumed to be due to minimal change disease (MCD) variant.Concomitant other progressive glomerulonephritis or non-immunologic glomerular disease such as diabetic nephropathy.Type 2 diabetes mellitus with Hemoglobin A1c (HbA1c) > 8% at Screening.Evidence of diabetic nephropathy on biopsy, history of diabetic microvascular or macrovascular disease (eg, diabetic retinopathy, peripheral neuropathy).Any diagnosed or suspected immunosuppressed or immunodeficient state such as asplenia, human immunodeficiency virus (HIV), primary immunodeficiencies, organ or bone marrow transplantation, with the exception of corneal transplants.Previously treated with immunosuppressive or other immunomodulatory agents such as but not limited to cyclophosphamide, rituximab, infliximab, eculizumab, canakinumab, mycophenolate mofetil (MMF) or mycophenolate sodium (MPS), cyclosporine, tacrolimus, sirolimus, everolimus, or systemic corticosteroids exposure (> 7.5 milligrams per deciliter [mg/d] prednisone/prednisolone equivalent) within 4 months (or 12 months for rituximab) prior to Screening.Participants currently treated with oral budesonide.Participants who have stopped this therapy ≥ 4 months prior to Screening may be eligible.Active clinically significant infections, known history of recurrent clinically significant infection, or Screening laboratory evidence consistent with an active infection, or IV anti-infectives (antibacterials, antiviral or antifungals).Participants with a history of opportunistic infections are excluded.Hypogammaglobulinemia: Serum Immunoglobin G (IgG) < 6.0 gram per litre (g/L), at Screening.
Sites
INECO Neurociencias Oroño - Rosario
Centro Integral de Medicina Respiratoria (CIMER) - Tucumán
Recruiting
FDI Clinical Research
Recruiting
StudyPREVAIL
SponsorBiogen
Study typeInterventional
Conditions
Iga nephropathy
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06935357
